Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 465

1.

Ten-year experience of the multidisciplinary Osteoncology Center.

Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T.

Support Care Cancer. 2019 Jan 16. doi: 10.1007/s00520-019-4635-5. [Epub ahead of print]

PMID:
30649614
2.

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.

Pietri E, Massa I, Bravaccini S, Ravaioli S, Tumedei MM, Petracci E, Donati C, Schirone A, Piacentini F, Gianni L, Nicolini M, Campadelli E, Gennari A, Saba A, Campi B, Valmorri L, Andreis D, Fabbri F, Amadori D, Rocca A.

Oncologist. 2018 Dec 27. pii: theoncologist.2018-0243. doi: 10.1634/theoncologist.2018-0243. [Epub ahead of print]

PMID:
30591548
3.

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.

Conteduca V, Gurioli G, Rossi L, Scarpi E, Lolli C, Schepisi G, Farolfi A, De Lisi D, Gallà V, Burgio SL, Menna C, Amadori A, Losi L, Amadori D, Costi MP, De Giorgi U.

BMC Cancer. 2018 Dec 19;18(1):1267. doi: 10.1186/s12885-018-5180-1.

4.

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.

Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, Bologna A, Gianni L, Rosetti F, Amaducci L, Cavanna L, Foca F, Sarti S, Serra P, Valmorri L, Bruzzi P, Corradengo D, Gennari A; MYME investigators.

Breast Cancer Res Treat. 2018 Dec 7. doi: 10.1007/s10549-018-05070-2. [Epub ahead of print]

PMID:
30536182
5.

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P.

Cancer Manag Res. 2018 Nov 14;10:5659-5666. doi: 10.2147/CMAR.S181570. eCollection 2018.

6.

Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age.

Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Endocr Connect. 2018 Dec 1. pii: EC-18-0478.R1. doi: 10.1530/EC-18-0478. [Epub ahead of print]

7.

Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial.

Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL, Amadori D, Passardi A.

Onco Targets Ther. 2018 Aug 29;11:5261-5268. doi: 10.2147/OTT.S166614. eCollection 2018.

8.

Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers.

Mercatali L, Serra P, Miserocchi G, Spadazzi C, Liverani C, De Vita A, Marisi G, Bongiovanni A, Recine F, Pangan A, Masalu N, Ibrahim T, Amadori D.

J Vis Exp. 2018 Jun 11;(136). doi: 10.3791/57113.

PMID:
29939179
9.

Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients.

Massa I, Nanni O, Foca F, Maltoni M, Derni S, Gentili N, Frassineti GL, Casadei Gardini A, Valgiusti M, Amadori D, Prati E, Altini M, Gallegati D, Sansoni E.

BMC Palliat Care. 2018 Jun 19;17(1):86. doi: 10.1186/s12904-018-0339-8.

10.

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?

Bronte G, Bravaccini S, Ravaioli S, Puccetti M, Scarpi E, Andreis D, Tumedei MM, Sarti S, Cecconetto L, Pietri E, De Simone V, Maltoni R, Bonafè M, Amadori D, Rocca A.

Transl Oncol. 2018 Aug;11(4):950-956. doi: 10.1016/j.tranon.2018.05.006. Epub 2018 Jun 18.

11.

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma.

De Vita A, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Recine F, Bongiovanni A, Pieri F, Cavaliere D, Fausti V, Amadori D, Ibrahim T.

J Vis Exp. 2018 Apr 11;(134). doi: 10.3791/56767.

PMID:
29708525
12.

Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?

Bravaccini S, Ravaioli S, Amadori D, Scarpi E, Puccetti M, Rocca A, Tumedei MM, Masalu N, Kahima J, Pangan A, Faustine L, Farolfi A, Maltoni R, Bonafè M, Serra P, Bronte G.

Front Endocrinol (Lausanne). 2018 Mar 29;9:137. doi: 10.3389/fendo.2018.00137. eCollection 2018.

13.

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

Bronte G, Rocca A, Ravaioli S, Puccetti M, Tumedei MM, Scarpi E, Andreis D, Maltoni R, Sarti S, Cecconetto L, Fedeli A, Pietri E, De Simone V, Asioli S, Amadori D, Bravaccini S.

BMC Cancer. 2018 Mar 27;18(1):348. doi: 10.1186/s12885-018-4239-3.

14.

Myxofibrosarcoma primary cultures: molecular and pharmacological profile.

De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T.

Ther Adv Med Oncol. 2017 Dec;9(12):755-767. doi: 10.1177/1758834017737472. Epub 2017 Oct 28.

15.

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.

Ulivi P, Canale M, Passardi A, Marisi G, Valgiusti M, Frassineti GL, Calistri D, Amadori D, Scarpi E.

Int J Mol Sci. 2018 Jan 20;19(1). pii: E307. doi: 10.3390/ijms19010307.

16.

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M.

Nat Commun. 2018 Jan 8;9(1):160. doi: 10.1038/s41467-017-02485-1.

17.

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.

De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T.

Int J Mol Sci. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662.

18.

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M.

Nat Commun. 2017 Nov 27;8(1):1801. doi: 10.1038/s41467-017-01562-9. Erratum in: Nat Commun. 2018 Jan 8;9(1):160.

19.

Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature.

Bongiovanni A, Recine F, Celli M, Marcantognini G, Foca F, Liverani C, Fausti V, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Medicine (Baltimore). 2017 Nov;96(46):e8567. doi: 10.1097/MD.0000000000008567. Review.

20.

Primary leiomyosarcoma of the bone: a case report and a review of the literature.

Recine F, Bongiovanni A, Casadei R, Pieri F, Riva N, De Vita A, Mercatali L, Liverani C, Spadazzi C, Miserocchi G, Fausti V, Amadori D, Ibrahim T.

Medicine (Baltimore). 2017 Nov;96(45):e8545. doi: 10.1097/MD.0000000000008545. Review.

21.

Management and potentialities of primary cancer cultures in preclinical and translational studies.

Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T.

J Transl Med. 2017 Nov 7;15(1):229. doi: 10.1186/s12967-017-1328-z. Review.

22.

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines.

Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T.

J Vis Exp. 2017 Sep 13;(127). doi: 10.3791/56311.

PMID:
28930982
23.

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.

Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D.

Sci Rep. 2017 Sep 5;7(1):10426. doi: 10.1038/s41598-017-11048-9.

24.

Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.

Mercatali L, La Manna F, Miserocchi G, Liverani C, De Vita A, Spadazzi C, Bongiovanni A, Recine F, Amadori D, Ghetti M, Ibrahim T.

Int J Mol Sci. 2017 Jul 29;18(8). pii: E1655. doi: 10.3390/ijms18081655.

25.

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.

Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, Casadei Gardini A, Monti M, Ruscelli S, Frassineti GL, Calistri D, Amadori D, Passardi A.

Int J Mol Sci. 2017 Jun 9;18(6). pii: E1240. doi: 10.3390/ijms18061240.

26.

The challenge of sustainability in healthcare systems: Frequency and cost of inappropriate patterns of breast cancer care (the E.Pic.A study).

Massa I, Balzi W, Burattini C, Gentili N, Bucchi L, Nanni O, Gallegati D, Pierini A, Amadori D, Falcini F, Altini M.

Breast. 2017 Aug;34:103-107. doi: 10.1016/j.breast.2017.05.007. Epub 2017 May 27.

27.

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.

Lolli C, Gallà V, Schepisi G, Barone D, Burgio SL, Maugeri A, Vertogen B, Amadori D, De Giorgi U.

Oncologist. 2017 Jul;22(7):784-e74. doi: 10.1634/theoncologist.2017-0154. Epub 2017 May 25.

28.

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, González Del Alba A, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G.

Ann Oncol. 2017 Jul 1;28(7):1508-1516. doi: 10.1093/annonc/mdx155.

29.

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Ragazzini A, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P.

Sci Rep. 2017 May 2;7(1):1293. doi: 10.1038/s41598-017-01420-0.

30.

Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania.

Masalu N, Serra P, Amadori D, Kahima J, Majinge C, Rwehabura J, Nanni O, Bravaccini S, Puccetti M, Tumino R, Bucchi L.

Int J Public Health. 2017 Sep;62(7):755-762. doi: 10.1007/s00038-017-0971-8. Epub 2017 Apr 19.

31.

Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.

Tedaldi G, Tebaldi M, Zampiga V, Danesi R, Arcangeli V, Ravegnani M, Cangini I, Pirini F, Petracci E, Rocca A, Falcini F, Amadori D, Calistri D.

Oncotarget. 2017 Jul 18;8(29):47064-47075. doi: 10.18632/oncotarget.16791.

32.

Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.

Rocca A, Cecconetto L, Passardi A, Melegari E, Andreis D, Monti M, Maltoni R, Sarti S, Pietri E, Schirone A, Fabbri F, Donati C, Nanni O, Fedeli A, Faedi M, Amadori D.

Cancer Chemother Pharmacol. 2017 May;79(5):863-871. doi: 10.1007/s00280-017-3279-8. Epub 2017 Mar 24.

33.

Sorafenib for the treatment of breast cancer.

Bronte G, Andreis D, Bravaccini S, Maltoni R, Cecconetto L, Schirone A, Farolfi A, Fedeli A, Serra P, Donati C, Amadori D, Rocca A.

Expert Opin Pharmacother. 2017 Apr;18(6):621-630. doi: 10.1080/14656566.2017.1309024. Epub 2017 Apr 7. Review.

PMID:
28335647
34.

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2017 Feb 23;10:1155-1164. doi: 10.2147/OTT.S127955. eCollection 2017. Review.

35.

CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):309. doi: 10.1242/bio.023911. No abstract available.

36.

Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.

Maltoni R, Casadio V, Ravaioli S, Foca F, Tumedei MM, Salvi S, Martignano F, Calistri D, Rocca A, Schirone A, Amadori D, Bravaccini S.

Oncotarget. 2017 Mar 7;8(10):16642-16649. doi: 10.18632/oncotarget.15120.

37.

The surgical pathology laboratory in Mwanza, Tanzania: a survey on the reproducibility of diagnoses after the first years of autonomous activity.

Tumino R, Rambau PF, Callea F, Leoncini L, Monaco R, Kahima J, Stracca Pansa V, Viberti L, Amadori D, Giovenali P, Mteta KA.

Infect Agent Cancer. 2017 Jan 21;12:6. doi: 10.1186/s13027-017-0115-z. eCollection 2017.

38.

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.

Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J.

J Clin Oncol. 2017 Apr 1;35(10):1041-1048. doi: 10.1200/JCO.2016.69.2871. Epub 2017 Jan 23. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):359.

PMID:
28113032
39.

Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway.

Amadori D, Serra P, Masalu N, Pangan A, Scarpi E, Bugingo AM, Katabalo D, Ibrahim T, Bongiovanni A, Miserocchi G, Spadazzi C, Liverani C, Turri V, Tedaldi R, Mercatali L.

Oncotarget. 2017 Feb 21;8(8):13142-13156. doi: 10.18632/oncotarget.14482.

40.

Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT.

Bongiovanni A, Recine F, Riva N, Foca F, Liverani C, Mercatali L, Nicolini S, Pieri F, Amadori D, Ibrahim T.

Clin Lung Cancer. 2017 Jul;18(4):415-420. doi: 10.1016/j.cllc.2016.11.004. Epub 2016 Nov 21.

PMID:
27956089
41.

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.

De Vita A, Miserocchi G, Recine F, Mercatali L, Pieri F, Medri L, Bongiovanni A, Cavaliere D, Liverani C, Spadazzi C, Amadori D, Ibrahim T.

Molecules. 2016 Dec 3;21(12). pii: E1662.

42.

Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.

Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E, Amadori D, Puisieux A, Rigaud M, Fabbri F.

Oncotarget. 2017 Jan 10;8(2):2423-2436. doi: 10.18632/oncotarget.13682.

43.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.

Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. doi: 10.1158/1078-0432.CCR-16-1025. Epub 2016 Nov 30.

44.

Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):133-140. doi: 10.1242/bio.022483. Erratum in: Biol Open. 2017 Feb 15;6(2):309.

45.

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.

Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T.

Int J Mol Sci. 2016 Nov 1;17(11). pii: E1827.

46.

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, Calistri D, Ludovini V, Crinò L, Amadori D, Ulivi P.

Clin Cancer Res. 2017 May 1;23(9):2195-2202. doi: 10.1158/1078-0432.CCR-16-0966. Epub 2016 Oct 25.

47.

Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.

Zampiga V, Danesi R, Tedaldi G, Tebaldi M, Cangini I, Pirini F, Pittureri C, Amaducci E, Guidi L, Faedi M, Amadori D, Falcini F, Calistri D.

Int J Biol Markers. 2016 Dec 23;31(4):e461-e465. doi: 10.5301/jbm.5000227.

PMID:
27516001
48.

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2016 Oct 11;9:6233-6246. eCollection 2016. Review.

49.

Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.

Casadei Gardini A, Tenti E, Masini C, Nanni O, Scarpi E, Valgiusti M, Restuccia S, Gallani ML, Palazzini S, Bianchini E, Menozzi S, Maugeri A, Amadori D, Minguzzi M, Frassineti GL.

Oncotarget. 2016 Jun 28;7(26):40719-40724. doi: 10.18632/oncotarget.8942.

50.

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

Salvi S, Casadio V, Conteduca V, Lolli C, Gurioli G, Martignano F, Schepisi G, Testoni S, Scarpi E, Amadori D, Calistri D, Attard G, De Giorgi U.

Oncotarget. 2016 Jun 21;7(25):37839-37845. doi: 10.18632/oncotarget.9341.

Supplemental Content

Loading ...
Support Center